Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

  PMID 42193276 · PMC13203762 · Biomedicines · 2026 · 8 claims · 8 setups

  Full-text index only

  PARPi + ARPi combinations are effective in ARPi-sensitive (C4-2B) and ARPi-resistant (AbiR, MDVR) prostate cancer models, but provide the greatest benefit in ARPi-sensitive cells

  c4-2b cck-8 morphology western

• Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.

  PMID 33634984 · PMC7882098 · Clinical and translational medicine · 2021 · 8 claims · 8 setups

  Has reproduction · 85

  JMJD6 is identified as a potent epigenetic vulnerability/fitness gene in RCC by integrating GeCK CRISPR screening data with TCGA-KIRC epigenetic regulator survival analysis

  pan-cancer tcga-kirc rcc balb crispr rna-seq mtt

• MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy.

  PMID 39805182 · PMC11780959 · Translational oncology · 2025 · 6 claims · 8 setups

  Full-text index only

  A C3 PCLAF+ tumor cell subtype identified by scRNA-seq shows high proliferation/differentiation potential and is linked to aggressive tumor behavior and poor prognosis in HR+BC

  hr+bc mda-mb-361 tcga scrna-seq cellchat pyscenic